Sienna Biopharmaceuticals, Inc. (SNNAQ)の価格はいくらですか

Sienna Biopharmaceuticals, Inc. (SNNAQ)の価格は$0.0001です

Sienna Biopharmaceuticals, Inc. (SNNAQ)の時価総額は何ですか

Sienna Biopharmaceuticals, Inc. (SNNAQ)の時価総額は$3.09Kです

Sienna Biopharmaceuticals, Inc.（SNNAQ）営業利益率

Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin. Among its pipeline, SNA-120 stood out as a pioneering, first-in-class inhibitor of tropomyosin receptor kinase A, undergoing Phase IIb clinical evaluation for addressing psoriasis and its associated itching. Another key candidate, SNA-125, a topical dual Janus kinase 3 inhibitor, progressed through Phase I/II clinical studies for conditions like atopic dermatitis, psoriasis, and pruritus. Furthermore, Sienna was advancing SNA-001, a topical suspension incorporating silver particles, into pivotal clinical trials not only for acne treatment but also for diminishing light-colored hair, encompassing shades such as white, gray, blonde, light brown, and light red. Established in 2010 and based in Westlake Village, California, the company originally operated as Sienna Labs, Inc. before rebranding as Sienna Biopharmaceuticals, Inc. in February 2016. However, the firm faced significant financial challenges, initiating Chapter 11 bankruptcy proceedings on September 16, 2019, which subsequently converted to Chapter 7 liquidation on December 18, 2019.

年	営業利益率	変化
提供された日付のデータは十分ではありません。

年

営業利益率

変化

提供された日付のデータは十分ではありません。

企業	営業利益率	営業利益率の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	38.97%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
UCB S.A. UCB.BR	31.23%	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR

企業

営業利益率

営業利益率の差

国